Background and Aims: Crohn's disease [CD] is a chronic inflammatory disease with unpredictable behaviour. More than half of CD patients eventually develop complications such as stenosis, for which they then require endoscopic dilatation or surgery, as no anti-fibrotic drugs are currently available. We aim to identify disease-modifying genes associated with fibrostenotic CD. Methods: We performed a within-case analysis comparing 'extreme phenotypes' using the Immunochip and replication of the top single nucleotide polymorphisms [SNPs] with Agena Bioscience in two independent case-control cohorts totalling 322 cases with fibrostenotis [recurrent after surgery] and 619 cases with purely inflammatory CD.
Results: Combined meta-analysis resulted in a genome-wide significant signal for SNP rs11861007 [p = 6.0910
Introduction
Crohn's sisease [CD] is a chronic inflammatory bowel disease [IBD] with unpredictable disease behaviour; more than half of CD patients eventually develop complications such as fistulae and stenosis. 1 Patients with fibrosis-induced stenosis require endoscopic dilatation or surgery, as no anti-fibrotic drugs are currently available. The estimated lifetime risk for surgery in CD patients is 70%, with fibrostenosis as the most common indication for surgery. 2 Within 18 months after surgery, the endoscopic recurrence rate of fibrostenosis is 40-60%. 3 Fibrostenosis of the intestine is a result of chronic inflammation: the permanent scarring and the consequent luminal narrowing is induced by continuous events of injury and healing. Finally, the intestine is no longer able to restore the normal histological configuration and excessive deposition of extracellular matrix prevails. This leads to thickening of the intestinal wall, which in turn leads to luminal stricturing, finally causing stenosis and obstruction.
Genetic studies of IBD have identified over 240 risk loci associated with disease development. 4, 5 A large genotype-phenotype association study was performed, including 34 819 IBD patients, which identified three loci [NOD2, MHC and MST1 3p21] associated with disease location. 6 However, only a few risk variants are known that influence disease behaviour, such as SMAD3 with recurrent surgery in CD, MAGI1 with complicated structuring CD, and FOXO3, XACT and IGFBP1-3 with severe disease course in CD. [7] [8] [9] [10] Variants associated with disease onset seem not to be associated with disease behaviour, which suggests that the biological pathways that underlie disease behaviour are distinct from those that underlie disease onset. 10 In this study, we aim to identify disease-modifying genes associated with the fibrostenotic phenotype in CD. This will help us gain insight into the biological mechanisms underlying intestinal fibrosis development, which might open new avenues for the treatment of CD.
We performed a within-case analysis comparing 'extreme phenotypes', an approach that provides power to detect associations within disease cohorts that has previously been successfully adopted for other traits, including obesity. 11, 12 We used an immune-focused fine mapping chip [Immunochip] with 166 251 single nucleotide polymorphisms [SNPs] , in two independent case-control cohorts totalling 322 individuals with multiple [two or more] resections due to confirmed ileal stenosis, which we used as cases, and which we compared to patients with 619 purely inflammatory CD [non-penetrating/non-fibrostenotic with disease duration > 5 years]. Following this approach, we identified and replicated a variant within lncRNA RP11-679B19.1 and in WWOX, as a disease-modifier, associated with recurrent fibrostenotic CD. We then studied the potential functional consequences of this variant by studying resection material of CD patients carrying the risk allele.
Methods

Genetic analysis [cohort description, quality control and statistical analysis]
Subjects
The discovery cohort consisted of 521 Dutch CD patients, selected out of ~ 1500 Dutch CD patients. Selection was based on reviewing the medical records of the total cohort of 1500 patients. We selected patients on extreme ends of the fibrostenotic phenotype: a case group and a control group. The case group consisted of 242 patients with 'recurrent fibrostenotic' CD, which was defined as the need for multiple [two or more] resections due to confirmed ileal stenosis. The control group consisted of 279 patients with purely inflammatory disease behaviour CD [Montreal classification B1 13 ] defined as non-penetrating, non-fibrostenotic CD with a disease duration of > 5 years, without the need for any kind of surgery. All patients of the discovery cohort were also included in the IIBDGC core-phenotype study. 6 For the replication phase, patients were selected from the Parelsnoer Institute database [http://www.parelsnoer.org/]. This database consists of 3394 IBD patients [CD: n = 2118] collected from the IBD Centres in all eight University Medical Centres in the Netherlands. Patients already included in the discovery phase were excluded. Eighty CD patients with recurrent fibrostenotic disease and 340 patients with purely inflammatory disease were selected with similar criteria. While the phenotypes of the discovery cohort could be checked against the patients' medical charts, regulations prevented us from doing the same with the replication cohort. Hence, the replication cohort might have some non-cases and/or non-controls admixed. All patients were of Central European descent.
Discovery phase
Immunochip genotyping
In the discovery phase of the study we used genotype data of ~1500 CD patients described by Jostins et al. 14 10, 16 In total, 43 SNPs passed the design of two plexes with the Assay Design suite of Agena Bioscience [https://seqpws1.agenacx.com/ AssayDesignerSuite.html].
Replication phase
Genotyping
Forty-three SNPs were genotyped using the Agena Bioscience Massarray in the replication phase [http://agenabio.com]. During QC we excluded SNPs with a Hardy-Weinberg equilibrium p-value < 0.0001 in controls and an overall call rate < 90% and individuals with < 85% of SNPs confidently genotyped. After QC, the replication cohort consisted of 80 CD cases with recurrent fibrostenotic disease behaviour, 340 CD patients with purely inflammatory disease and 39 SNPs with a genotype call rate of 99%. Since rs11861007 failed the Agena Bioscience design and it was the only Immunochip SNP in the WWOX region, genotyping of SNP rs11861007 was performed using Taqman technology [Applied Biosystems]. Given that the prevalence of recurrent stenotic disease in CD was 0.04 in our replication cohort, that the allele frequency of our rs11861007 risk allele A is 0.06 in Caucasian patients of Western and Central European descent (CEU), and that we expected the risk variant to have an odds ratio [OR] of 4.3, we expected to have > 80% power to discover this association in our replication cohort. Ultimately, we only had 60% power to detect the association that we did detect for rs11861007 in our replication cohort at an OR of 2.1 [http://zzz.bwh.harvard.edu/gpc/cc2.html].
Statistical analysis
SNP annotation
LocusZoom was used to construct regional association plots 17 [Supplementary Figure S1] . Exploration of the linkage disequilibrium [r 2 > 0.8] was performed with Haploview. 18 We assessed whether associated SNPs had known functional consequences or regulatory features. The Encyclopedia of DNA Elements [ENCODE] 19 was searched using the UCSC Genome Browser. 20 Specifically, SNPs located in the following regulatory features were searched: DNaseIhypersensitivity sites, transcription factor binding sites, histone modification and DNA-polymerase sites. We tested whether associated variants [ 21 Additional enhancer analyses were performed with the Fantom5 enhancer atlas. 22 
In silico analysis [rs11861007]
The strongest association for fibrostenotic disease was found in the RP11-679B19.1 lncRNA, and in the WWOX gene. The function of the RP11-679B19.1 lncRNA is unknown. To predict in which biological or cellular process and molecular function the WWOX gene is involved, we used an in-house developed RNA network tool [http://www.genenetwork.nl]. 23 The RNA network uses a method, based on principal component analysis, to build transcriptional profiles for biological pathways, which can be used to predict gene functions. A more detailed description of the method of the RNA network can be found in the paper by Fehrmann et al. As stenotic tissue is a final stage in the process of fibrosis formation, we considered the stenotic tissue, medial part of the resection, as not representative. Therefore, we included only samples of the ileum and colon, respectively proximal and distal from the stenosis. Pathology records of the resection material were checked and revealed no severe inflammation or fibrosis at the end of the resection sides, proximal and distal, of the stenosis. 
Genotyping and patient selection
Results
In this study we included two independent case-control cohorts totalling 322 recurrent fibrostenotic and 619 purely inflammatory CD cases; 60% of the cohort were female with a mean age at diagnosis of 25 years. The cohorts were selected based on 'extreme phenotypes', resulting in a statistically significant difference in disease location and behaviour between patients [ Table 1 ]. After analysis of 166 251 SNPs in 242 fibrostenotic and 279 purely inflammatory CD cases and replication of 34 selected SNPs in an independent cohort of 80 fibrostenotic and 340 purely inflammatory CD cases, the combined meta-analysis resulted in a genomewide significant signal for SNP rs11861007 [p = 6.09 × 10 -11 , OR = 3.2, heterogeneity [I 2 ] < 75%] [ Table 2 , Supplementary Table S1 ]. The minor heterogeneity for SNP rs11861007 between the discovery and the replication cohort might be caused by a slight admixture of non-cases and/or non-controls in the replication cohort, as described in the Methods section. To assess whether the association between rs11861007 and fibrostenotic disease was not mainly due to ileal disease localization we tested this marker for association with ileal disease localization. We found no association between rs11861007 and ileal disease localization [p = 0.27]. Additional logistic regression analyses for the association between SNP rs11861007 and re-fibrosis, with disease location as a covariate, still showed a significant association [p = 0.004]. We also tested for an association between rs11861007 and the Montreal Class B2 phenotype [any stricuring disease] in our cohort, but did not find an association [p = 0.25]. 22 WWOX is the only coding gene in the locus [defined as 250 kb on either side of our top hit] making it the most likely positional candidate gene. The SNP is also located in the lncRNA RP11-679B19.1, in which it might affect folding, but for this lnRNA there is also no eQTL effect, and no function is known for RP11-679B19.1.
SNP annotation and in silico analyses
Co-transcriptional pathway analysis using an in-house-developed RNA network tool 23 
Expression analyses
Normal ileal and colonic tissue residing proximal to and distal from the stenotic part was sampled from five CD patients heterozygous for the WWOX risk allele [A] and five CD patients homozygous for the WWOX wild-type allele [G] . WWOX mRNA levels were similar in both the ileal and the colonic tissue of patients with or without the risk allele [Supplementary Figure S2] . In contrast, TGF-β expression was significantly higher in the colonic tissue of risk-allele-carrying patients compared to patients homozygous for the wild-type allele 
Discussion
In this study, we have identified a variant in the WWOX gene as a disease-modifier associated with a recurrent fibrostenotic phenotype in CD, and we have replicated this association in an independent 4.1 [6.5] This table provides the clinical characteristics of patients with recurrent fibrostenotic and purely inflammatory CD in the combined cohort. Disease location and behaviour is based on the Montreal classification for CD. Chi-squared and Mann-Whitney U-tests [only for age of onset] are used to calculate the p-value. CD, Crohn's disease; IQR, interquartile range. cohort. We found that patients carrying the risk allele show enhanced profibrotic signalling, through higher expression of tumour growth factor-β [TGF-β], in the colon. This suggests that the genetic variant in WWOX is associated with a decrease of WWOX function. Alternatively, the effect could be caused by a configuration change of the lnRNA RP11-679B19.1, which has recently been recorded in the same locus and is, yet, of unknown function.
The genetic variants that contribute to disease behaviour can be different from the variants that contribute to disease susceptibility. This has been shown for a variant affecting FOXO3A expression, which was found to be significantly associated with disease prognosis but which was not associated with CD susceptibility. 16 In this study, we confirm the concept that disease-modifying genes can differ from variants contributing to disease development. The SNP found to be most closely associated [rs11861007] has not been associated with disease development in previous studies. 4 Previous genotype-phenotype studies in IBD patients have not studied the specific phenotype in the present study: recurring ileal fibrostenosis in CD. 6 Previous studies focusing on genetic variants associated with a single fibrotic event in CD found associations with variants in SMAD3 and MAGI, but due to the diverse coverage of the genotyping platforms we could not replicate these findings. 7, 8 We could also not confirm a previously described association between NOD2 variants and ileal fibrostenotic disease, which might be due to the fact that we studied recurrent fibrostenosis, not necessarily ileal, or because the NOD2 variants are relatively rare in our cohort.
The SNP [rs11861007] is located in an intron close to exon 9 of the WWOX gene. Although we could not find an eQTL effect, regulatory features or enhancer activity, the WWOX gene is the only coding gene in the locus [defined as 250 kb on either side of our top hit] making it the most likely positional candidate gene. The SNP is also located in the lncRNA RP11-679B19.1, in which it might affect folding, but for this lnRNA there is also no eQTL effect, and no function is known for RP11-679B19.1. WWOX is a known tumour suppressor gene and encodes a protein that contains two WW domains and a short-chain dehydrogenase/reductase domain [SRD] . The mechanism of tumour suppression of WWOX involves apoptosis, modulation of the extracellular matrix and modulation of cell bioenergetics 24 Genome-wide association studies have shown that WWOX also plays a role in the pathogenesis of pulmonary fibrosis. 25 Targeted deletion of Wwox in epithelium in the mammary gland increased fibronectin levels 24 and conditional deletion of Wwox in the mammary gland significantly upregulated multiple collagen genes. 26 Moreover, molecular functions predicted by our RNA network tool show that WWOX plays a role in fibrosis formation, in agreement with the previously described literature reports.
The main mediator between intestinal inflammation and fibrosis in IBD is TGF-β, 27 which is overexpressed in intestinal tissue in CD patients. 28 Upon TGF-β stimulation, WWOX acts as an inhibitor of SMAD3 transcriptional activity by sequestering it in the cytoplasm. 29 We show an enhanced TGF-β expression in CD patients carrying the WWOX risk allele. TGF-β stimulates downstream signalling pathways resulting in expression of several profibrotic genes, including CTGF. qPCR analysis of CTGF in this study showed a trend towards increased expression in the WWOX risk-allele-carrying CD patients compared to the patients homozygous for the WWOX wildtype allele. We conclude that WWOX risk-allele-carrying individuals have enhanced TGF-β expression with a trend towards elevated expression of profibrotic genes as a downstream effect.
There are some limitations to this study. First, the cohort size is relatively small. However, by using a within-case analysis comparing 'extreme phenotypes' we increased the power of our analysis. This approach provides power to detect associations within disease cohorts and the approach has been successfully adopted for other traits. 11, 12 Moreover, we replicated our findings in an independent cohort. Second, the upregulation of TGF-β in the ileal part of the resection material [upstream of the stenosis] in patients carrying the WWOX risk allele was a trend and not statistically significant. However, in the colonic part of the resection material [downstream of the stenosis] in patients carrying the WWOX risk allele we do show statistically significant enhanced TGF-β expression. All available WWOX risk-allele-carrying patients in our centre were included, but because the risk allele has a low frequency this number is quite small, which means our study is relatively underpowered. Increasing the sample size may turn the trend we observe into a significant association. Finally, the WWOX-SMAD3-TGF-β pathway has been described previously 29 and it has been proven that the proteins encoded by the genes interact, although the exact pathways through which they interact have not yet been elucidated, making it difficult to interpret the results from our study.
In conclusion, we have identified and replicated WWOX as a disease-modifying gene associated with the recurrent fibrostenotic phenotype in CD. Our expression analyses suggest a functional effect of the risk allele through enhanced expression of TGF-β in risk-allele carriers, indicating profibrotic expression. CD patients carrying the WWOX risk allele appear to have a profibrotic profile. To avoid fibrotic complications, it might be advisable to refrain from prescribing anti-inflammatory medication that enhances TGF-β signalling in intestinal fibroblasts in these patients. . CD, Crohn's disease; qPCR, quantification polymerase chain reaction; TGF-β, transforming growth factor; CTGF, connective tissue growth factor; homozyg, homozygous; heterozyg, heterozygous.
